CASE TX/4-32366A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mall Lebel Number

June 13, 2005

Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BAENTELI ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/02710

FILED: 14 MARCH 2003

U.S. APPLICATION NO: 10/507,060

35 USC §371 DATE: Herewith

FOR: 2,4-DIAMINOPYRIMIDINE DERIVATIVES

MS: PCT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 9, 2004. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7909 Date: June 13, 2005 Thomas R. Savitsky Attorney for Applicants Reg. No. 31,661 NOV-21-2005 11:52

NOVARTIS INTELLECT PROP



973 781 8064

P.31

Sheet 1 of 2

ATTY. DOCKET NO. TX/4-32386A APPLICATION NO.

10/507,060 APPLICANT BAENTELI ET AL. FILING DATE

Group

FORM PTO-1449
(REV. 7-85)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

			U.S.	PATENT DOCUMENTS				
EXAMINER INITIAL	П	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
INITIAL	AA	5,958,935	9/28/99	Davis et al.	514	275	11/1	9/96
	AB	6,048,866	4/11/00	Hutchings et al.	514	272	3/13	1/98
	AC	6,337,335	1/8/02	Hutchings et al.	514	272	10/2	20/99
	AD							
	AE							
	AF							
	AG							
	AH							
	Al		:					
	AJ						ļ	<u>.</u>
.,	AK						_	·
	AL						<u> </u>	
			FORE	GN PATENT DOCUMENTS	S			
··· <u> </u>		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YEŞ	SLATION NO
<del></del>	AM	0 945 443	2/12/03	EP				
	AN	95/15952	6/15/95	wo				
	AO	96/28427	9/19/96	wo				
	AP	98/11094	3/19/98	wo				
	AQ	98/16547	4/16/98	wo				
		OTHER DOC	LIMENTS	(Including Author, Title, Date,	Pertinent pages, E	itc.)	-	
		OTTER DOC		(marada para)				
	AR							
	ļ							
	AS							
	AT.							

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

NOV-21-2005 11:53

**FORM PTO-1449** 

NOVARTIS INTELLECT PROP



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(REV. 7-85) PATENT AND TRADEMARK OFF INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

973 781 8064

Sheet 2 of 2

ATTY. DOCKET NO. TX/4-32366A APPLICATION NO. 10/507,060 APPLICANT BAENTELI ET AL. FILING DATE

Group

P.32

## FOREIGN PATENT DOCUMENTS

ENAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLAS\$	\$UBCLASS	IRAN YES	SLATIO NO
· ·	CA	98/41512	9/24/98	wo				
	СВ	00/27825	5/18/00	wo				
	CC	00/31068	6/2/00	wo				
	CD	00/33844	6/15/00	wo				
	CE	00/78731	12/28/00	wo				
	CF	01/25220	4/12/01	wo				
	CG	01/27089	4/19/01	wo				
<del></del>	СН	01/29009	4/26/01	wo				
	CI	01/32632	5/10/01	wo				
	ĊJ	01/47897	7/5/01	wo				
	СК	01/62233	6/7/01	wo			口	
	CL	01/65656	9/7/01	wo				
	СМ	02/56888	7/25/02	wo				
	CN							
	ÇO							
	ÇP							
	ÇQ							
	CR					<u> </u>		
	CS							
	CT							
	CU							
	ÇV		m :					
	cw	:						
	СХ							
	CY							
	CZ	•		•				

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.